PRECISE-AD Study:Trying a new treatment for Early Alzheimer's disease
The PRECISE-AD study is a phase 1 clinical trial, sponsored by ProMis Neurosciences, for people with mild cognitive impairment (MCI) to mild dementia due to Alzheimer's disease. It tests a new antibody treatment (PMN310), given by IV, that is designed to help slow down the disease. Participation includes 12 infusions over 1 year.
Study highlights
Key information about the PRECISE-AD study
- Age 50 and older
- Early Alzheimer's Disease
- Study partner (friend or family) required
- Infusion
- Study zone: Southern California
Study goal and design
Advancing precision medicine in early Alzheimer's disease
The PRECISE-AD study is testing a new IV treatment called PMN310 in people with early Alzheimer's. It looks at whether the drug is safe, well-tolerated, how it works in the body, and whether it might help slow the disease by targeting amyloid-beta. PMN310 is investigational and not yet approved by the FDA.
Study-related care and support
Comprehensive medical oversight and biomarker analysis
While contributing to research, participants receive:
- The possibility to receive PMN310 investigational study medication
- Advanced biomarker testing and brain imaging
- Regular cognitive assessments and memory evaluations
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journey
A structured research experience
Express your interest
Answer a questionnaire to check preliminary criteria.
Meet the study team
Complete a detailed brain and memory evaluation.
Begin treatment (or placebo)
Receive PMN310 or placebo by IV infusion once every 4 weeks, for a total of 12 infusions over 1 year.
Continue the study
Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Ready to get involved?Join the PRECISE-AD study.
Contribute to progress, support research, help others, and care for your health.